Moderna Beats Revenue Forecast Ahead of Crucial Flu Vaccine Call

Moderna has beaten Wall Street revenue estimates just days before a major US regulatory decision. The quarterly revenue surprise comes as the company prepares for the FDA's verdict on its flu vaccine.

The decision could become a turning point for Moderna as it works to reduce its dependence on COVID-19 products. Investors are also tracking updates on its vaccine pipeline and cost-cutting efforts.

The vaccine maker reported second-quarter revenue of USD 145 million. Analysts had expected about USD 103 million. Strong international demand for its COVID-19 vaccine and partnership payments from countries including the UK, Canada, and Australia supported the better-than-expected result.

Despite posting a loss of USD 1.97 per share, Moderna still performed better than market expectations. Analysts had projected a wider loss of USD 2.08 per share.

FDA Decision Could Shape Moderna's Next Growth Phase

The company is now awaiting an FDA decision on its mRNA-based seasonal flu vaccine by August 5. Approval would make it Moderna's first flu vaccine in the United States using mRNA technology. It would also help the company expand beyond COVID-19 vaccines.

The vaccine has already received unanimous backing from an FDA advisory committee. However, the final regulatory decision remains crucial for its commercial launch. Industry experts believe approval would strengthen Moderna's long-term vaccine portfolio.

The company continues to expect revenue growth of up to 10% during 2026. Around half of its annual revenue is expected to come from the US market. Management also reduced its research and development spending forecast to improve financial discipline.

Also Read: AI in Drug Discovery and Development: From Lab to Commercial Market

Pipeline Shows Progress Despite Norovirus Setback

Not every update was positive. Moderna said its norovirus vaccine candidate failed to meet statistical criteria for early success during an interim Phase 3 analysis. The company will continue the trial by enrolling another group of participants.

Meanwhile, the company continues to develop a personalized cancer vaccine with Merck. Late-stage melanoma trial results are expected later this year. Positive data could provide another important growth opportunity beyond infectious diseases.

Investors also welcomed Moderna's continued focus on lowering expenses. Research spending declined compared with last year. The company also improved its operating expense outlook for the full year.

Key Highlights

• Revenue reached USD 145 million, beating analyst estimates.
• International vaccine sales supported quarterly performance.
• FDA decision on the flu vaccine is expected by August 5.
• Approval could expand Moderna beyond COVID-19 vaccines.
• Norovirus vaccine trial faced an interim setback.
• Personalized cancer vaccine program continues with Merck.
• Moderna maintained its 2026 revenue growth forecast of up to 10%.